Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.
about
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functionsNf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG developmentSpatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domainsMouse models of neurofibromatosis 1 and 2.A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue SarcomasEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formationMerlin Isoforms 1 and 2 Both Act as Tumour Suppressors and Are Required for Optimal Sperm MaturationNF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin.The importance of nerve microenvironment for schwannoma development.A critical role for NF2 and the Hippo pathway in branching morphogenesisUnfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressorMerlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survivalThe NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivatorsNF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctionsThe tumor suppressor merlin is required for cell cycle exit, terminal differentiation, and cell polarity in the developing murine lensInvestigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cellsQuantitative assessment of whole-body tumor burden in adult patients with neurofibromatosisMerlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma modelAnti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.Merlin/ERM proteins establish cortical asymmetry and centrosome position.The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex.Optimizing biologically targeted clinical trials for neurofibromatosis.Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane.Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasmsLoss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.Treatment of vestibular schwannoma cells with ErbB inhibitorsPreclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.A novel imaging-compatible sciatic nerve schwannoma modelGrowth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary studyIdentification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.
P2860
Q24299493-E427B355-D275-474B-AB17-585687EDF6B5Q24307540-16FC5176-C3A3-4091-9FF8-B51C45635FF0Q24323074-04DAAA55-8979-48C7-8A22-03393BD116CAQ24533435-139456C0-0B14-4414-AB3D-C1862F51F708Q24682869-798B3A14-1108-4061-888D-C4E88DBBDF75Q26782842-7EA3DBD4-BFD9-436C-9552-D0050C5C39D3Q26827810-000E4DAF-9446-497E-B178-02676B2087EEQ27301307-6E002D55-5A78-49A3-BA13-BB1BD71809D9Q27304868-45271048-45D5-4E7D-83AA-9BD7E2F4CAD7Q27309867-3A9BD72E-A4E2-46A8-A0C0-7A2CC122836BQ27321805-2691BFD2-BC41-47C6-B92F-0374BCED5230Q27334571-91F9538B-FB98-496F-A8DD-685DB3556AA9Q27675130-3BA1F9A9-21F0-4878-9B94-D434C9D88CA8Q28283076-E696A6B4-8DC3-43C8-8059-7155D766182BQ28363493-A75FAACE-7A72-41EF-B041-CC5B9AEDBBAAQ28504464-B3A5D67B-5A8A-49D8-A410-02A088E367FCQ28511556-E16A6140-F537-41DF-ACCB-F81A00A41C01Q28590774-94D66339-160B-4F28-B891-246064EBBA0DQ28728224-142FA361-EFF4-4AFD-AA71-495F5D315F45Q28730289-68660AE0-FF76-4A4C-B915-B723B8197AFBQ30373369-C2C6FAD2-CBA4-4A91-A1CB-20BB697C9F79Q30383248-A8A38019-3B72-492B-AAE2-64BF54701A0BQ30388655-5D9E82DC-4EB0-4517-8178-D8C3EEDF9AA0Q30401833-82CB8708-4EE6-4B26-BBE8-54043BEF9DE8Q30406342-D7609D73-B966-4927-9E4E-E2DDB4B75598Q30418605-2E0DCB7B-0963-4E68-8147-0DA76A4E6E1BQ30418770-795B9BE0-8D31-45E9-B9DD-030EC8D95F67Q30429717-E3F2DD9B-FD11-45CD-8474-66D56E74527AQ30438898-B8D38E5B-1153-46E6-B736-D621281F2C64Q30443237-5F92CC1B-ACBE-4F88-B612-AEE1D6C45F03Q30443407-593772F4-6D76-4AAB-94C0-C1EF914EE7F2Q30457681-E67595D5-F652-4C02-A9E9-039972C705E2Q30458195-C1802FBD-0E0B-4D1D-89CD-7D0F951A7E25Q30458767-62C0C7EC-9815-4086-A4F7-47DAE8998ADFQ30459589-6B947B44-E99A-4B64-A1A6-97A5EB2138EFQ30464276-6ABECF7E-D91A-4BB1-9AB4-45582E60F449Q30471189-14885937-51E3-4BF4-ABE9-232FFE9F0D19Q30481231-35AB5B8A-C5DF-4A67-9615-038859EF302EQ30487287-A8C93236-3B50-4C6C-8224-0BBA421EC5E8Q30495325-DFB26170-E458-4878-90AD-727FD728C8BC
P2860
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Conditional biallelic Nf2 muta ...... human neurofibromatosis type 2
@nl
Conditional biallelic Nf2 muta ...... uman neurofibromatosis type 2.
@ast
Conditional biallelic Nf2 muta ...... uman neurofibromatosis type 2.
@en
type
label
Conditional biallelic Nf2 muta ...... human neurofibromatosis type 2
@nl
Conditional biallelic Nf2 muta ...... uman neurofibromatosis type 2.
@ast
Conditional biallelic Nf2 muta ...... uman neurofibromatosis type 2.
@en
prefLabel
Conditional biallelic Nf2 muta ...... human neurofibromatosis type 2
@nl
Conditional biallelic Nf2 muta ...... uman neurofibromatosis type 2.
@ast
Conditional biallelic Nf2 muta ...... uman neurofibromatosis type 2.
@en
P2093
P2860
P3181
P1433
P1476
Conditional biallelic Nf2 muta ...... uman neurofibromatosis type 2.
@en
P2093
E Robanus-Maandag
J M Woodruff
L Goutebroze
M Giovannini
M Niwa-Kawakita
M van der Valk
V Abramowski
P2860
P304
P3181
P577
2000-07-01T00:00:00Z